These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1369122)

  • 61. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Recent progress and prospect in oligonucleotide therapeutics].
    Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T
    Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antisense therapy for cancer.
    Gleave ME; Monia BP
    Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nucleic acid-based drugs against emerging zoonotic viruses.
    Wong JP
    Future Med Chem; 2015; 7(13):1709-19. PubMed ID: 26399689
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.
    Detrick B; Nagineni CN; Grillone LR; Anderson KP; Henry SP; Hooks JJ
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):163-9. PubMed ID: 11133862
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.
    Danis RP; Henry SP; Ciulla TA
    Expert Opin Pharmacother; 2001 Feb; 2(2):277-91. PubMed ID: 11336586
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Progress in antisense therapeutics discovery and development.
    Crooke ST
    Ciba Found Symp; 1997; 209():158-64; discussion 164-8. PubMed ID: 9383575
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antisense therapeutics: from theory to clinical practice.
    Pirollo KF; Rait A; Sleer LS; Chang EH
    Pharmacol Ther; 2003 Jul; 99(1):55-77. PubMed ID: 12804699
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
    Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
    Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
    [No Abstract]   [Full Text] [Related]  

  • 72. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
    Burnett JR
    Curr Opin Mol Ther; 2006 Oct; 8(5):461-7. PubMed ID: 17078389
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Oligonucleotide therapeutics: 25 years agrowing.
    Goodchild J
    Curr Opin Mol Ther; 2004 Apr; 6(2):120-8. PubMed ID: 15195922
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A status update of modified oligonucleotides for chemotherapeutics applications.
    Sanghvi YS
    Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.
    Rigo F; Seth PP; Bennett CF
    Adv Exp Med Biol; 2014; 825():303-52. PubMed ID: 25201110
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The concept and application of antisense oligonucleotides.
    Yacyshyn BR; Crooke ST
    Dis Colon Rectum; 2001 Sep; 44(9):1241-3. PubMed ID: 11584192
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 2'-Modified oligonucleotides for antisense therapeutics.
    Prakash TP; Bhat B
    Curr Top Med Chem; 2007; 7(7):641-9. PubMed ID: 17430205
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [TBL] [Abstract][Full Text] [Related]  

  • 79. First antisense drug trials planned in leukemia.
    Reynolds T
    J Natl Cancer Inst; 1992 Mar; 84(5):288-90. PubMed ID: 1738177
    [No Abstract]   [Full Text] [Related]  

  • 80. Antisense oligonucleotides: the state of the art.
    Aboul-Fadl T
    Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.